Would the FDA would block the development of a drug like...

Would the FDA would block the development of a drug like Ceflatonin (homoharringtonine) to enable big money competitors to target the market.

My dearest friend, Sylvia Hart, is a patient at M. D. Anderson Cancer Center in Houston, Texas and
she is suffering from Chronic Myleogenous Leukemia, referred to as CML. She has undergone
treatment with 4 previous chemotherapies, all of which have lost their effectiveness or caused her
severe allergic reactions. For the past two years she has been part of a clinical drug study at M. D.
Anderson and is being treated with Homoharringtonine (“HHT”). She has felt better on HHT than
with anything else since she was diagnosed 7 years ago.
On Wednesday, October 29ti, the Federal Drug Administration put a “hold” on this drug. There was
no advance notice and no explanation! She was to receive her next treatment the following day on
Thursday, October 30*. The M. D. Anderson doctors are presenting individual cases to Oncopharm
Corporation, the drug company involved, and then will meet with the FDA in order to see if they
may continue treating certain people. While waiting for the outcome, Sylvia and other patients may
be switched to other drugs that are less effective for them, and their blood chemistry could be thrown
out of balance. In Sylvia’s case, being out of balance could become terminal very quickly.
Without this HHT treatment there is only one other trial drug treatment which may not even work
for her. If there is any way you could possibly help speed up this process I would appreciate it
immensely.